Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Pyrimidinones"" wg kryterium: Temat


Tytuł :
Relugolix for the treatment of uterine fibroids.
Autorzy :
Rocca ML; Operative Unit of Obstetric and Gynaecology, Giovanni Paolo II Hospital , Lamezia Terme, Italy.
Palumbo AR; Department of Clinical and Experimental Medicine, Unit of Obstetrics and Gynaecology, 'Magna Graecia' University , Catanzaro, Italy.
Lico D; Department of Clinical and Experimental Medicine, Unit of Obstetrics and Gynaecology, 'Magna Graecia' University , Catanzaro, Italy.
Fiorenza A; Department of Clinical and Experimental Medicine, Unit of Obstetrics and Gynaecology, 'Magna Graecia' University , Catanzaro, Italy.
Bitonti G; Department of Clinical and Experimental Medicine, Unit of Obstetrics and Gynaecology, 'Magna Graecia' University , Catanzaro, Italy.
D'Agostino S; Department of Clinical and Experimental Medicine, Unit of Obstetrics and Gynaecology, 'Magna Graecia' University , Catanzaro, Italy.
Gallo C; Department of Clinical and Experimental Medicine, Unit of Obstetrics and Gynaecology, 'Magna Graecia' University , Catanzaro, Italy.
Di Carlo C; Department of Clinical and Experimental Medicine, Unit of Obstetrics and Gynaecology, 'Magna Graecia' University , Catanzaro, Italy.
Zullo F; Department of Neurosciences, Reproductive and Dentistry Sciences, University of Naples 'Federico II' , Naples, Italy.
Venturella R; Department of Clinical and Experimental Medicine, Unit of Obstetrics and Gynaecology, 'Magna Graecia' University , Catanzaro, Italy.
Pokaż więcej
Źródło :
Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2020 Oct; Vol. 21 (14), pp. 1667-1674. Date of Electronic Publication: 2020 Jul 17.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Leiomyoma/*drug therapy
Phenylurea Compounds/*therapeutic use
Pyrimidinones/*therapeutic use
Receptors, LHRH/*antagonists & inhibitors
Uterine Neoplasms/*drug therapy
Female ; Humans ; Hysterectomy ; Leiomyoma/metabolism ; Leiomyoma/surgery ; Menstruation/drug effects ; Phenylurea Compounds/administration & dosage ; Phenylurea Compounds/adverse effects ; Phenylurea Compounds/pharmacokinetics ; Premenopause/drug effects ; Pyrimidinones/administration & dosage ; Pyrimidinones/adverse effects ; Pyrimidinones/pharmacokinetics ; Randomized Controlled Trials as Topic ; Treatment Outcome ; Uterine Neoplasms/metabolism ; Uterine Neoplasms/surgery
Czasopismo naukowe
Tytuł :
One-pot three component synthesis of substituted dihydropyrimidinones using fruit juices as biocatalyst and their biological studies.
Autorzy :
Gulati S; Department of Chemistry, Chaudhary Charan Singh Haryana Agricultural University, Hisar, India.
Singh R; Department of Chemistry, Chaudhary Charan Singh Haryana Agricultural University, Hisar, India.
Prakash R; Department of Soil Science, Chaudhary Charan Singh Haryana Agricultural University, Hisar, India.
Sangwan S; Department of Chemistry, Chaudhary Charan Singh Haryana Agricultural University, Hisar, India.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Sep 15; Vol. 15 (9), pp. e0238092. Date of Electronic Publication: 2020 Sep 15 (Print Publication: 2020).
Typ publikacji :
Journal Article
MeSH Terms :
Biocatalysis*
Fruit and Vegetable Juices*
Antifungal Agents/*chemistry
Antifungal Agents/*pharmacology
Pyrimidinones/*chemistry
Pyrimidinones/*pharmacology
Anti-Bacterial Agents/chemical synthesis ; Anti-Bacterial Agents/chemistry ; Anti-Bacterial Agents/pharmacology ; Antifungal Agents/chemical synthesis ; Chemistry Techniques, Synthetic ; Herbicides/chemical synthesis ; Herbicides/chemistry ; Herbicides/pharmacology ; Pyrimidinones/chemical synthesis
Czasopismo naukowe
Tytuł :
Dabrafenib plus trametinib in patients with BRAF -mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.
Autorzy :
Subbiah V; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: .
Lassen U; Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Élez E; Medical Oncology Department, Vall d'Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain.
Italiano A; Early Phase Trials and Sarcoma Units, Institut Bergonié, Bordeaux, France.
Curigliano G; Division of Early Drug Development, Istituto Europeo di Oncologia, IRCCS, and University of Milano, Milan, Italy.
Javle M; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
de Braud F; Dipartimento di Oncologia, Istituto Nazionale dei Tumori, Milan, Italy.
Prager GW; Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University Vienna, Vienna, Austria.
Greil R; Third Medical Department, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute, CCS Salzburg, Salzburg, Austria.
Stein A; Department of Internal Medicine II (Oncology Center), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Fasolo A; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
Schellens JHM; Department of Clinical Pharmacology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, Netherlands.
Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Viele K; Berry Consultants, Austin, TX, USA; Department of Biostatistics, University of Kentucky, Lexington, KY, USA.
Boran AD; Precision Medicine, Novartis Pharmaceuticals, East Hanover, NJ, USA.
Gasal E; Global Drug Development, Novartis Pharmaceuticals, East Hanover, NJ, USA.
Burgess P; Global Drug Development, Novartis Pharma, Basel, Switzerland.
Ilankumaran P; Global Drug Development, Novartis Pharmaceuticals, East Hanover, NJ, USA.
Wainberg ZA; Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Sep; Vol. 21 (9), pp. 1234-1243. Date of Electronic Publication: 2020 Aug 17.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Biliary Tract Neoplasms/*drug therapy
Imidazoles/*administration & dosage
Oximes/*administration & dosage
Proto-Oncogene Proteins B-raf/*genetics
Pyridones/*administration & dosage
Pyrimidinones/*administration & dosage
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Biliary Tract Neoplasms/genetics ; Biliary Tract Neoplasms/pathology ; Disease-Free Survival ; Female ; Humans ; Imidazoles/adverse effects ; Male ; Middle Aged ; Mutation/genetics ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/pathology ; Oximes/adverse effects ; Pyridones/adverse effects ; Pyrimidinones/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Autorzy :
Huijberts SCFA; Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands. .
van Geel RMJM; Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht, The Netherlands.; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.
van Brummelen EMJ; Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.; Centre for Human Drug Research, Leiden, The Netherlands.
Opdam FL; Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands. .
Marchetti S; Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.
Steeghs N; Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.
Pulleman S; Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.
Thijssen B; Department of Pharmacy, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Rosing H; Department of Pharmacy, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Monkhorst K; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Huitema ADR; Department of Pharmacy, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.
Beijnen JH; Department of Pharmacy, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Utrecht University, Utrecht, The Netherlands.
Bernards R; Division of Molecular Carcinogenesis, Oncode Institute and The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Schellens JHM; Utrecht University, Utrecht, The Netherlands.
Pokaż więcej
Źródło :
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2020 May; Vol. 85 (5), pp. 917-930. Date of Electronic Publication: 2020 Apr 09.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/genetics
Lapatinib*/administration & dosage
Lapatinib*/adverse effects
Lapatinib*/pharmacokinetics
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/genetics
Pyridones*/administration & dosage
Pyridones*/adverse effects
Pyridones*/pharmacokinetics
Pyrimidinones*/administration & dosage
Pyrimidinones*/adverse effects
Pyrimidinones*/pharmacokinetics
Proto-Oncogene Proteins p21(ras)/*genetics
Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols ; Dose-Response Relationship, Drug ; Drug Monitoring/methods ; Female ; Humans ; Male ; Middle Aged ; Mutation ; Pharmacogenetics ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Autorzy :
Shore ND; From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network, Interfaculty Initiative in Information Studies-Graduate School of Interdisciplinary Information Studies, University of Tokyo, Tokyo (H.A.); the Department of Radiation Oncology, Gustave Roussy Cancer Institute, Villejuif, France (A.B.); Myovant Sciences, Brisbane, CA (D.F.V., B.S., X.F., V.K., J.W.); and Service d'Urologie, Cliniques Universitaires Saint Luc, Brussels (B.T.).
Saad F; From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network, Interfaculty Initiative in Information Studies-Graduate School of Interdisciplinary Information Studies, University of Tokyo, Tokyo (H.A.); the Department of Radiation Oncology, Gustave Roussy Cancer Institute, Villejuif, France (A.B.); Myovant Sciences, Brisbane, CA (D.F.V., B.S., X.F., V.K., J.W.); and Service d'Urologie, Cliniques Universitaires Saint Luc, Brussels (B.T.).
Cookson MS; From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network, Interfaculty Initiative in Information Studies-Graduate School of Interdisciplinary Information Studies, University of Tokyo, Tokyo (H.A.); the Department of Radiation Oncology, Gustave Roussy Cancer Institute, Villejuif, France (A.B.); Myovant Sciences, Brisbane, CA (D.F.V., B.S., X.F., V.K., J.W.); and Service d'Urologie, Cliniques Universitaires Saint Luc, Brussels (B.T.).
George DJ; From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network, Interfaculty Initiative in Information Studies-Graduate School of Interdisciplinary Information Studies, University of Tokyo, Tokyo (H.A.); the Department of Radiation Oncology, Gustave Roussy Cancer Institute, Villejuif, France (A.B.); Myovant Sciences, Brisbane, CA (D.F.V., B.S., X.F., V.K., J.W.); and Service d'Urologie, Cliniques Universitaires Saint Luc, Brussels (B.T.).
Saltzstein DR; From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network, Interfaculty Initiative in Information Studies-Graduate School of Interdisciplinary Information Studies, University of Tokyo, Tokyo (H.A.); the Department of Radiation Oncology, Gustave Roussy Cancer Institute, Villejuif, France (A.B.); Myovant Sciences, Brisbane, CA (D.F.V., B.S., X.F., V.K., J.W.); and Service d'Urologie, Cliniques Universitaires Saint Luc, Brussels (B.T.).
Tutrone R; From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network, Interfaculty Initiative in Information Studies-Graduate School of Interdisciplinary Information Studies, University of Tokyo, Tokyo (H.A.); the Department of Radiation Oncology, Gustave Roussy Cancer Institute, Villejuif, France (A.B.); Myovant Sciences, Brisbane, CA (D.F.V., B.S., X.F., V.K., J.W.); and Service d'Urologie, Cliniques Universitaires Saint Luc, Brussels (B.T.).
Akaza H; From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network, Interfaculty Initiative in Information Studies-Graduate School of Interdisciplinary Information Studies, University of Tokyo, Tokyo (H.A.); the Department of Radiation Oncology, Gustave Roussy Cancer Institute, Villejuif, France (A.B.); Myovant Sciences, Brisbane, CA (D.F.V., B.S., X.F., V.K., J.W.); and Service d'Urologie, Cliniques Universitaires Saint Luc, Brussels (B.T.).
Bossi A; From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network, Interfaculty Initiative in Information Studies-Graduate School of Interdisciplinary Information Studies, University of Tokyo, Tokyo (H.A.); the Department of Radiation Oncology, Gustave Roussy Cancer Institute, Villejuif, France (A.B.); Myovant Sciences, Brisbane, CA (D.F.V., B.S., X.F., V.K., J.W.); and Service d'Urologie, Cliniques Universitaires Saint Luc, Brussels (B.T.).
van Veenhuyzen DF; From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network, Interfaculty Initiative in Information Studies-Graduate School of Interdisciplinary Information Studies, University of Tokyo, Tokyo (H.A.); the Department of Radiation Oncology, Gustave Roussy Cancer Institute, Villejuif, France (A.B.); Myovant Sciences, Brisbane, CA (D.F.V., B.S., X.F., V.K., J.W.); and Service d'Urologie, Cliniques Universitaires Saint Luc, Brussels (B.T.).
Selby B; From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network, Interfaculty Initiative in Information Studies-Graduate School of Interdisciplinary Information Studies, University of Tokyo, Tokyo (H.A.); the Department of Radiation Oncology, Gustave Roussy Cancer Institute, Villejuif, France (A.B.); Myovant Sciences, Brisbane, CA (D.F.V., B.S., X.F., V.K., J.W.); and Service d'Urologie, Cliniques Universitaires Saint Luc, Brussels (B.T.).
Fan X; From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network, Interfaculty Initiative in Information Studies-Graduate School of Interdisciplinary Information Studies, University of Tokyo, Tokyo (H.A.); the Department of Radiation Oncology, Gustave Roussy Cancer Institute, Villejuif, France (A.B.); Myovant Sciences, Brisbane, CA (D.F.V., B.S., X.F., V.K., J.W.); and Service d'Urologie, Cliniques Universitaires Saint Luc, Brussels (B.T.).
Kang V; From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network, Interfaculty Initiative in Information Studies-Graduate School of Interdisciplinary Information Studies, University of Tokyo, Tokyo (H.A.); the Department of Radiation Oncology, Gustave Roussy Cancer Institute, Villejuif, France (A.B.); Myovant Sciences, Brisbane, CA (D.F.V., B.S., X.F., V.K., J.W.); and Service d'Urologie, Cliniques Universitaires Saint Luc, Brussels (B.T.).
Walling J; From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network, Interfaculty Initiative in Information Studies-Graduate School of Interdisciplinary Information Studies, University of Tokyo, Tokyo (H.A.); the Department of Radiation Oncology, Gustave Roussy Cancer Institute, Villejuif, France (A.B.); Myovant Sciences, Brisbane, CA (D.F.V., B.S., X.F., V.K., J.W.); and Service d'Urologie, Cliniques Universitaires Saint Luc, Brussels (B.T.).
Tombal B; From the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); the University of Montreal Hospital Center, Montreal (F.S.); the Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City (M.S.C.); the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC (D.J.G.); Urology San Antonio, San Antonio, TX (D.R.S.); Chesapeake Urology, Towson, MD (R.T.); the Department of Strategic Investigation on Comprehensive Cancer Network, Interfaculty Initiative in Information Studies-Graduate School of Interdisciplinary Information Studies, University of Tokyo, Tokyo (H.A.); the Department of Radiation Oncology, Gustave Roussy Cancer Institute, Villejuif, France (A.B.); Myovant Sciences, Brisbane, CA (D.F.V., B.S., X.F., V.K., J.W.); and Service d'Urologie, Cliniques Universitaires Saint Luc, Brussels (B.T.).
Pokaż więcej
Corporate Authors :
HERO Study Investigators
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Jun 04; Vol. 382 (23), pp. 2187-2196. Date of Electronic Publication: 2020 May 29.
Typ publikacji :
Clinical Trial, Phase III; Comparative Study; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma/*drug therapy
Antineoplastic Agents, Hormonal/*therapeutic use
Gonadotropin-Releasing Hormone/*antagonists & inhibitors
Leuprolide/*therapeutic use
Phenylurea Compounds/*therapeutic use
Prostatic Neoplasms/*drug therapy
Pyrimidinones/*therapeutic use
Testosterone/*blood
Adenocarcinoma/blood ; Administration, Oral ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Hormonal/adverse effects ; Cardiovascular Diseases/chemically induced ; Gonadotropin-Releasing Hormone/agonists ; Humans ; Injections, Subcutaneous ; Leuprolide/adverse effects ; Male ; Middle Aged ; Phenylurea Compounds/adverse effects ; Prostatic Neoplasms/blood ; Pyrimidinones/adverse effects
Czasopismo naukowe
Tytuł :
Structure-Activity Relationship of SPOP Inhibitors against Kidney Cancer.
Autorzy :
Dong Z; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Wang Z; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Guo ZQ; Department of Urology, Zhongnan Hospital of Wuhan University, Hubei 430071, China.; CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, China.
Gong S; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Zhang T; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Liu J; CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, China.
Luo C; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, UCAS, Hangzhou 310024, China.
Jiang H; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, UCAS, Hangzhou 310024, China.; Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTec University, Shanghai 201210, China.
Yang CG; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, UCAS, Hangzhou 310024, China.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2020 May 14; Vol. 63 (9), pp. 4849-4866. Date of Electronic Publication: 2020 Apr 27.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*pharmacology
Nuclear Proteins/*antagonists & inhibitors
Pyridines/*pharmacology
Pyrimidinones/*pharmacology
Repressor Proteins/*antagonists & inhibitors
Antineoplastic Agents/chemical synthesis ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Drug Screening Assays, Antitumor ; HEK293 Cells ; Humans ; Kidney Neoplasms/drug therapy ; Molecular Structure ; Nuclear Proteins/metabolism ; PTEN Phosphohydrolase/metabolism ; Protein Binding/drug effects ; Pyridines/chemical synthesis ; Pyrimidinones/chemical synthesis ; Repressor Proteins/metabolism ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Trametinib Toxicities in Patients With Low-grade Gliomas and Diabetes Insipidus: Related Findings?
Autorzy :
Egan G; Division of Haematology/Oncology.
Hamilton J; Division of Endocrinology, The Hospital for Sick Children.
McKeown T; Division of Haematology/Oncology.
Bouffet E; Division of Haematology/Oncology.
Tabori U; Division of Haematology/Oncology.
Dirks P; Divison of Neurosurgery, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Bartels U; Division of Haematology/Oncology.
Pokaż więcej
Źródło :
Journal of pediatric hematology/oncology [J Pediatr Hematol Oncol] 2020 May; Vol. 42 (4), pp. e248-e250.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Diabetes Insipidus*/drug therapy
Diabetes Insipidus*/metabolism
Diabetes Insipidus*/pathology
Eye Neoplasms*/drug therapy
Eye Neoplasms*/metabolism
Eye Neoplasms*/pathology
Glioma*/drug therapy
Glioma*/metabolism
Glioma*/pathology
Hypothalamic Neoplasms*/drug therapy
Hypothalamic Neoplasms*/metabolism
Pyridones/*adverse effects
Pyrimidinones/*adverse effects
Child ; Female ; Humans ; Pyridones/administration & dosage ; Pyrimidinones/administration & dosage
Czasopismo naukowe
Tytuł :
Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer.
Autorzy :
Kim RD; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Electronic address: .
McDonough S; SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
El-Khoueiry AB; University of Southern California, Los Angeles, CA, USA.
Bekaii-Saab TS; Ohio State University, Columbus, OH, USA.
Stein SM; Rutgers Cancer Institute, New Brunswick, NJ, USA.
Sahai V; University of Michigan, Ann Arbor, MI, USA.
Keogh GP; Charleston Hematology Oncology Associates, Southeast COR NCORP, Charleston, SC, USA.
Kim EJ; University of California Davis Cancer Center, Sacramento, CA, USA.
Baron AD; California Pacific Medical Center/Sutter Cancer Research Consortium, San Francisco, CA, USA.
Siegel AB; Columbia University, Columbia MU-NCORP, New York, NY, USA.
Barzi A; University of Southern California, Los Angeles, CA, USA.
Guthrie KA; SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Javle M; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hochster H; Rutgers Cancer Institute, New Brunswick, NJ, USA.
Pokaż więcej
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 May; Vol. 130, pp. 219-227. Date of Electronic Publication: 2020 Mar 29.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Biliary Tract Neoplasms/*drug therapy
Capecitabine/*therapeutic use
Fluorouracil/*therapeutic use
Pyridones/*therapeutic use
Pyrimidinones/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Biliary Tract Neoplasms/pathology ; Capecitabine/pharmacology ; Female ; Fluorouracil/pharmacology ; Humans ; Male ; Middle Aged ; Pyridones/pharmacology ; Pyrimidinones/pharmacology
Czasopismo naukowe
Tytuł :
The population growth, development and metabolic enzymes of the white-backed planthopper, Sogatella furcifera (Hemiptera: Delphacidae) under the sublethal dose of triflumezopyrim.
Autorzy :
Chen L; Biorational Pesticide Research Lab, Sichuan Agricultural University, Chengdu, 611130, China.
Wang X; Biorational Pesticide Research Lab, Sichuan Agricultural University, Chengdu, 611130, China. Electronic address: .
Zhang Y; Biorational Pesticide Research Lab, Sichuan Agricultural University, Chengdu, 611130, China.
Yang R; Biorational Pesticide Research Lab, Sichuan Agricultural University, Chengdu, 611130, China.
Zhang S; Biorational Pesticide Research Lab, Sichuan Agricultural University, Chengdu, 611130, China.
Xu X; Sichuan Provincial Plant Protection Station, Department of Agriculture, Chengdu, 610041, China.
Zhu M; Biorational Pesticide Research Lab, Sichuan Agricultural University, Chengdu, 611130, China.
Gong C; Biorational Pesticide Research Lab, Sichuan Agricultural University, Chengdu, 611130, China.
Hasnain A; Biorational Pesticide Research Lab, Sichuan Agricultural University, Chengdu, 611130, China.
Shen L; Biorational Pesticide Research Lab, Sichuan Agricultural University, Chengdu, 611130, China.
Jiang C; Biorational Pesticide Research Lab, Sichuan Agricultural University, Chengdu, 611130, China.
Pokaż więcej
Źródło :
Chemosphere [Chemosphere] 2020 May; Vol. 247, pp. 125865. Date of Electronic Publication: 2020 Jan 08.
Typ publikacji :
Journal Article
MeSH Terms :
Hemiptera/*drug effects
Hemiptera/*enzymology
Insect Control/*methods
Insecticides/*pharmacology
Pyridines/*pharmacology
Pyrimidinones/*pharmacology
Animals ; Cytochrome P-450 Enzyme System/metabolism ; Dose-Response Relationship, Drug ; Egg Proteins/genetics ; Egg Proteins/metabolism ; Female ; Fertility/drug effects ; Hemiptera/genetics ; Insecticides/administration & dosage ; Population Growth ; Pyridines/administration & dosage ; Pyrimidinones/administration & dosage ; Receptors, Cell Surface/genetics ; Receptors, Cell Surface/metabolism ; Reproduction/drug effects ; Survival Analysis ; Vitellogenins/genetics ; Vitellogenins/metabolism
Czasopismo naukowe
Tytuł :
Synthesis and bioevaluation of new vascular-targeting and anti-angiogenic thieno[2,3-d]pyrimidin-4(3H)-ones.
Autorzy :
Gold M; Organic Chemistry Laboratory, University Bayreuth, Universitaetsstrasse 30, 95440, Bayreuth, Germany.
Köhler L; Organic Chemistry Laboratory, University Bayreuth, Universitaetsstrasse 30, 95440, Bayreuth, Germany.
Lanzloth C; Organic Chemistry Laboratory, University Bayreuth, Universitaetsstrasse 30, 95440, Bayreuth, Germany.
Andronache I; Research Center for Integrated Analysis and Territorial Management, University of Bucharest, 4-12, Regina Elisabeta Avenue, Bucharest, 3rd District, 030018, Romania.
Anant S; Department of Cancer Biology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA.
Dandawate P; Department of Cancer Biology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA.
Biersack B; Organic Chemistry Laboratory, University Bayreuth, Universitaetsstrasse 30, 95440, Bayreuth, Germany.
Schobert R; Organic Chemistry Laboratory, University Bayreuth, Universitaetsstrasse 30, 95440, Bayreuth, Germany. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2020 Mar 01; Vol. 189, pp. 112060. Date of Electronic Publication: 2020 Jan 09.
Typ publikacji :
Journal Article
MeSH Terms :
Angiogenesis Inhibitors/*pharmacology
Pyrimidinones/*pharmacology
Thiophenes/*pharmacology
Angiogenesis Inhibitors/chemical synthesis ; Angiogenesis Inhibitors/metabolism ; Animals ; Binding Sites ; CDC2 Protein Kinase/metabolism ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Chickens ; Drug Screening Assays, Antitumor ; G2 Phase Cell Cycle Checkpoints/drug effects ; Humans ; Molecular Docking Simulation ; Molecular Structure ; Protein Binding ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/metabolism ; Protein Kinase Inhibitors/pharmacology ; Pyrimidinones/chemical synthesis ; Pyrimidinones/metabolism ; Structure-Activity Relationship ; Swine ; Thiophenes/chemical synthesis ; Thiophenes/metabolism ; Tubulin/metabolism ; Tubulin Modulators/chemical synthesis ; Tubulin Modulators/metabolism ; Tubulin Modulators/pharmacology ; Zebrafish
Czasopismo naukowe
Tytuł :
Discovery of a Novel, Highly Potent, and Selective Thieno[3,2- d ]pyrimidinone-Based Cdc7 Inhibitor with a Quinuclidine Moiety (TAK-931) as an Orally Active Investigational Antitumor Agent.
Autorzy :
Kurasawa O; Pharmaceutical Research Division , Takeda Pharmaceutical Company, Ltd. , 26-1, Muraoka-Higashi 2-chome , Fujisawa , Kanagawa 251-8555 , Japan.
Miyazaki T; Pharmaceutical Research Division , Takeda Pharmaceutical Company, Ltd. , 26-1, Muraoka-Higashi 2-chome , Fujisawa , Kanagawa 251-8555 , Japan.
Homma M; Pharmaceutical Research Division , Takeda Pharmaceutical Company, Ltd. , 26-1, Muraoka-Higashi 2-chome , Fujisawa , Kanagawa 251-8555 , Japan.
Oguro Y; Pharmaceutical Research Division , Takeda Pharmaceutical Company, Ltd. , 26-1, Muraoka-Higashi 2-chome , Fujisawa , Kanagawa 251-8555 , Japan.
Imada T; Pharmaceutical Research Division , Takeda Pharmaceutical Company, Ltd. , 26-1, Muraoka-Higashi 2-chome , Fujisawa , Kanagawa 251-8555 , Japan.
Uchiyama N; Pharmaceutical Research Division , Takeda Pharmaceutical Company, Ltd. , 26-1, Muraoka-Higashi 2-chome , Fujisawa , Kanagawa 251-8555 , Japan.
Iwai K; Pharmaceutical Research Division , Takeda Pharmaceutical Company, Ltd. , 26-1, Muraoka-Higashi 2-chome , Fujisawa , Kanagawa 251-8555 , Japan.
Yamamoto Y; Pharmaceutical Research Division , Takeda Pharmaceutical Company, Ltd. , 26-1, Muraoka-Higashi 2-chome , Fujisawa , Kanagawa 251-8555 , Japan.
Ohori M; Pharmaceutical Research Division , Takeda Pharmaceutical Company, Ltd. , 26-1, Muraoka-Higashi 2-chome , Fujisawa , Kanagawa 251-8555 , Japan.
Hara H; Pharmaceutical Research Division , Takeda Pharmaceutical Company, Ltd. , 26-1, Muraoka-Higashi 2-chome , Fujisawa , Kanagawa 251-8555 , Japan.
Sugimoto H; Pharmaceutical Research Division , Takeda Pharmaceutical Company, Ltd. , 26-1, Muraoka-Higashi 2-chome , Fujisawa , Kanagawa 251-8555 , Japan.
Iwata K; Pharmaceutical Sciences , Takeda Pharmaceutical Company, Ltd. , 26-1, Muraoka-Higashi 2-chome , Fujisawa , Kanagawa 251-8555 , Japan.
Skene R; Takeda California, Inc. , 10410 Science Center Drive , San Diego , California 92121 , United States.
Hoffman I; Takeda California, Inc. , 10410 Science Center Drive , San Diego , California 92121 , United States.
Ohashi A; Pharmaceutical Research Division , Takeda Pharmaceutical Company, Ltd. , 26-1, Muraoka-Higashi 2-chome , Fujisawa , Kanagawa 251-8555 , Japan.
Nomura T; Pharmaceutical Research Division , Takeda Pharmaceutical Company, Ltd. , 26-1, Muraoka-Higashi 2-chome , Fujisawa , Kanagawa 251-8555 , Japan.
Cho N; Pharmaceutical Research Division , Takeda Pharmaceutical Company, Ltd. , 26-1, Muraoka-Higashi 2-chome , Fujisawa , Kanagawa 251-8555 , Japan.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2020 Feb 13; Vol. 63 (3), pp. 1084-1104. Date of Electronic Publication: 2020 Jan 14.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Cell Cycle Proteins/*antagonists & inhibitors
Protein Kinase Inhibitors/*therapeutic use
Protein-Serine-Threonine Kinases/*antagonists & inhibitors
Pyrazolones/*therapeutic use
Pyrimidines/*therapeutic use
Pyrimidinones/*therapeutic use
Quinuclidines/*therapeutic use
Thiophenes/*therapeutic use
Animals ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/metabolism ; Binding Sites ; Cell Cycle Proteins/chemistry ; Cell Cycle Proteins/metabolism ; Cell Line, Tumor ; Drug Design ; Drug Discovery ; Formaldehyde/chemistry ; Humans ; Mice ; Molecular Docking Simulation ; Molecular Structure ; Protein Binding ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/metabolism ; Protein-Serine-Threonine Kinases/chemistry ; Protein-Serine-Threonine Kinases/metabolism ; Pyrazolones/pharmacology ; Pyrimidines/pharmacology ; Pyrimidinones/chemical synthesis ; Pyrimidinones/metabolism ; Quinuclidines/chemical synthesis ; Quinuclidines/metabolism ; Structure-Activity Relationship ; Thiophenes/chemical synthesis ; Thiophenes/metabolism ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Discovery of a Covalent Inhibitor of KRAS (AMG 510) for the Treatment of Solid Tumors.
Autorzy :
Lanman BA
Allen JR
Allen JG
Amegadzie AK
Ashton KS
Booker SK
Chen JJ
Chen N
Frohn MJ
Goodman G
Kopecky DJ
Liu L
Lopez P
Low JD
Ma V
Minatti AE
Nguyen TT
Nishimura N
Pickrell AJ
Reed AB
Shin Y
Siegmund AC
Tamayo NA
Tegley CM
Walton MC
Wang HL
Wurz RP
Xue M
Yang KC
Achanta P
Bartberger MD
Canon J
Hollis LS
McCarter JD
Mohr C
Rex K
Saiki AY
San Miguel T
Volak LP
Wang KH
Whittington DA
Zech SG
Lipford JR
Cee VJ
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2020 Jan 09; Vol. 63 (1), pp. 52-65. Date of Electronic Publication: 2019 Dec 24.
Typ publikacji :
News; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Neoplasms/*drug therapy
Piperazines/*therapeutic use
Proto-Oncogene Proteins p21(ras)/*antagonists & inhibitors
Pyridines/*therapeutic use
Pyrimidines/*therapeutic use
Pyrimidinones/*therapeutic use
Animals ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/pharmacokinetics ; Clinical Trials as Topic ; Dogs ; Drug Discovery ; Humans ; Isomerism ; Madin Darby Canine Kidney Cells ; Mice, Inbred BALB C ; Mice, Nude ; Mutation ; Piperazines/chemistry ; Piperazines/pharmacology ; Proto-Oncogene Proteins p21(ras)/genetics ; Pyridines/chemistry ; Pyridines/pharmacokinetics ; Pyridines/pharmacology ; Pyrimidines/chemistry ; Pyrimidines/pharmacology ; Pyrimidinones/chemistry ; Pyrimidinones/pharmacokinetics ; Rats ; Structure-Activity Relationship
Periodyk
Tytuł :
Establishment of a novel human cell line retaining the characteristics of the original pancreatic adenocarcinoma, and evaluation of MEK as a therapeutic target.
Autorzy :
Du X; Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China.
He K; Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China.
Huang Y; Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China.
Xu Z; Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China.
Kong M; Department of Pathology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China.
Zhang J; Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China.
Cao J; Clinical Research Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, P.R. China.
Teng L; Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China.
Pokaż więcej
Źródło :
International journal of oncology [Int J Oncol] 2020 Mar; Vol. 56 (3), pp. 761-771. Date of Electronic Publication: 2020 Jan 20.
Typ publikacji :
Journal Article
MeSH Terms :
Carcinoma, Pancreatic Ductal/*drug therapy
Cell Culture Techniques/*methods
Pancreatic Neoplasms/*drug therapy
Protein Kinase Inhibitors/*administration & dosage
Pyridones/*administration & dosage
Pyrimidinones/*administration & dosage
Animals ; Carcinoma, Pancreatic Ductal/genetics ; Carcinoma, Pancreatic Ductal/pathology ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Female ; Humans ; Mice ; Mutation ; Pancreatic Neoplasms/genetics ; Pancreatic Neoplasms/pathology ; Protein Kinase Inhibitors/pharmacology ; Pyridones/pharmacology ; Pyrimidinones/pharmacology ; Signal Transduction/drug effects ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Gut dysbiosis: not only with checkpoint inhibitors!
Autorzy :
Piroth M; Dermatology Department, CHU Nantes, University of Nantes, Nantes, France.
Frenard C; Dermatology Department, CHU Nantes, University of Nantes, Nantes, France.; CRCINA, University of Nantes, Nantes, France.
Quereux G; Dermatology Department, CHU Nantes, University of Nantes, Nantes, France.; CRCINA, University of Nantes, Nantes, France.
Khammari A; Dermatology Department, CHU Nantes, University of Nantes, Nantes, France.; CRCINA, University of Nantes, Nantes, France.
Corvec S; Bacteriology and Hygiene Department, Hôtel-Dieu, Nantes University Hospital, CRCINA, University of Nantes, Nantes, France.
Dréno B; Dermatology Department, CHU Nantes, University of Nantes, Nantes, France.; CRCINA, University of Nantes, Nantes, France.
Pokaż więcej
Źródło :
Clinical and experimental dermatology [Clin Exp Dermatol] 2020 Mar; Vol. 45 (2), pp. 247-249. Date of Electronic Publication: 2019 Jun 21.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Bacterial Translocation*
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Dysbiosis/*etiology
Enterobacter cloacae/*physiology
Gastrointestinal Microbiome/*drug effects
Imidazoles/*adverse effects
Melanoma/*secondary
Oximes/*adverse effects
Pyridones/*adverse effects
Pyrimidinones/*adverse effects
Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Enterobacter cloacae/isolation & purification ; Fatal Outcome ; Feces/microbiology ; Female ; Humans ; Imidazoles/administration & dosage ; Melanoma/drug therapy ; Oximes/administration & dosage ; Pyridones/administration & dosage ; Pyrimidinones/administration & dosage
Czasopismo naukowe
Tytuł :
Nucleobase mutants of a bacterial preQ 1 -II riboswitch that uncouple metabolite sensing from gene regulation.
Autorzy :
Dutta D; Department of Biochemistry and Biophysics and Center for RNA Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642.
Wedekind JE; Department of Biochemistry and Biophysics and Center for RNA Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642 .
Pokaż więcej
Źródło :
The Journal of biological chemistry [J Biol Chem] 2020 Feb 28; Vol. 295 (9), pp. 2555-2567. Date of Electronic Publication: 2019 Oct 28.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Gene Expression Regulation, Bacterial*
Mutation*
Pyrimidinones/*metabolism
Pyrroles/*metabolism
Riboswitch/*genetics
Base Sequence ; Binding Sites ; Pyrimidinones/analysis ; Pyrroles/analysis ; RNA, Bacterial/genetics
Czasopismo naukowe
Tytuł :
Stepwise Folding and Self-Assembly of a Merocyanine Folda-Pentamer.
Autorzy :
Hu X; Institut für Organische Chemie , Universität Würzburg , Am Hubland , 97074 Würzburg , Germany.
Lindner JO; Center for Nanosystems Chemistry , Universität Würzburg , Theodor-Boveri-Weg , 97074 Würzburg , Germany.
Würthner F; Institut für Organische Chemie , Universität Würzburg , Am Hubland , 97074 Würzburg , Germany.; Center for Nanosystems Chemistry , Universität Würzburg , Theodor-Boveri-Weg , 97074 Würzburg , Germany.
Pokaż więcej
Źródło :
Journal of the American Chemical Society [J Am Chem Soc] 2020 Feb 19; Vol. 142 (7), pp. 3321-3325. Date of Electronic Publication: 2020 Feb 05.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Coloring Agents/*chemistry
Polymers/*chemistry
Pyrimidinones/*chemistry
Coloring Agents/chemical synthesis ; Molecular Conformation ; Polymers/chemical synthesis ; Pyrimidinones/chemical synthesis
Czasopismo naukowe
Tytuł :
Myasthenia gravis following dabrafenib and trametinib for metastatic melanoma.
Autorzy :
Zaloum A; From the Departments of Neurology and Neurosurgery (A.Z., J.-P.R.F., C.C.) and Oncology (A.E.), McGill University, Montreal, Canada. .
Falet JR; From the Departments of Neurology and Neurosurgery (A.Z., J.-P.R.F., C.C.) and Oncology (A.E.), McGill University, Montreal, Canada.
Elkrief A; From the Departments of Neurology and Neurosurgery (A.Z., J.-P.R.F., C.C.) and Oncology (A.E.), McGill University, Montreal, Canada.
Chalk C; From the Departments of Neurology and Neurosurgery (A.Z., J.-P.R.F., C.C.) and Oncology (A.E.), McGill University, Montreal, Canada.
Pokaż więcej
Źródło :
Neurology [Neurology] 2020 Feb 18; Vol. 94 (7), pp. 322-323. Date of Electronic Publication: 2019 Dec 30.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Imidazoles/*therapeutic use
Melanoma/*drug therapy
Myasthenia Gravis/*etiology
Oximes/*therapeutic use
Pyridones/*therapeutic use
Pyrimidinones/*therapeutic use
Skin Neoplasms/*drug therapy
Aged ; Antineoplastic Agents/adverse effects ; Humans ; Imidazoles/adverse effects ; Male ; Melanoma/genetics ; Neoplasm Metastasis/drug therapy ; Neoplasm Metastasis/genetics ; Oximes/adverse effects ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/therapeutic use ; Pyridones/adverse effects ; Pyrimidinones/adverse effects ; Scalp ; Skin Neoplasms/genetics
Czasopismo naukowe
Tytuł :
Discovery, Structural Optimization, and Mode of Action of Essramycin Alkaloid and Its Derivatives as Anti-Tobacco Mosaic Virus and Anti-Phytopathogenic Fungus Agents.
Autorzy :
Wang T; National-Local Joint Engineering Laboratory for Energy Conservation in Chemical Process Integration and Resources Utilization, School of Chemical Engineering and Technology , Hebei University of Technology , Tianjin 300130 , China.
Yang S; National-Local Joint Engineering Laboratory for Energy Conservation in Chemical Process Integration and Resources Utilization, School of Chemical Engineering and Technology , Hebei University of Technology , Tianjin 300130 , China.
Li H; National-Local Joint Engineering Laboratory for Energy Conservation in Chemical Process Integration and Resources Utilization, School of Chemical Engineering and Technology , Hebei University of Technology , Tianjin 300130 , China.
Lu A; National-Local Joint Engineering Laboratory for Energy Conservation in Chemical Process Integration and Resources Utilization, School of Chemical Engineering and Technology , Hebei University of Technology , Tianjin 300130 , China.
Wang Z; Tianjin Key Laboratory of Structure and Performance for Functional Molecules, MOE Key Laboratory of Inorganic-Organic Hybrid Functional Material Chemistry, College of Chemistry , Tianjin Normal University , Tianjin 300387 , China.
Yao Y; National-Local Joint Engineering Laboratory for Energy Conservation in Chemical Process Integration and Resources Utilization, School of Chemical Engineering and Technology , Hebei University of Technology , Tianjin 300130 , China.
Wang Q; State Key Laboratory of Elemento-Organic Chemistry, Research Institute of Elemento-Organic Chemistry, College of Chemistry, Collaborative Innovation Center of Chemical Science and Engineering (Tianjin) , Nankai University , Tianjin 300071 , China.
Pokaż więcej
Źródło :
Journal of agricultural and food chemistry [J Agric Food Chem] 2020 Jan 15; Vol. 68 (2), pp. 471-484. Date of Electronic Publication: 2019 Dec 31.
Typ publikacji :
Journal Article
MeSH Terms :
Alkaloids/*chemistry
Antiviral Agents/*chemistry
Fungicides, Industrial/*chemistry
Pyrimidinones/*chemistry
Tobacco Mosaic Virus/*drug effects
Triazoles/*chemistry
Alkaloids/pharmacology ; Antiviral Agents/pharmacology ; Fungi/drug effects ; Fungi/physiology ; Fungicides, Industrial/pharmacology ; Molecular Structure ; Plant Diseases/microbiology ; Pyrimidinones/pharmacology ; Structure-Activity Relationship ; Tobacco Mosaic Virus/physiology ; Triazoles/pharmacology ; Virus Assembly/drug effects
Czasopismo naukowe
Tytuł :
Apparent darkening of scalp hair related to pili multigemini Following dabrafenib and trametinib.
Autorzy :
Avila C
Hoffman K
Milani-Nejad N
Pootrakul L; Division of Dermatology, The Ohio State University Department of Internal Medicine, Columbus, OH. .
Pokaż więcej
Źródło :
Dermatology online journal [Dermatol Online J] 2020 Jan 15; Vol. 26 (1). Date of Electronic Publication: 2020 Jan 15.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Hair Diseases/*chemically induced
Hair Follicle/*abnormalities
Imidazoles/*adverse effects
Oximes/*adverse effects
Pigmentation Disorders/*chemically induced
Pyridones/*adverse effects
Pyrimidinones/*adverse effects
Hair ; Humans ; Imidazoles/therapeutic use ; Male ; Melanoma/drug therapy ; Melanoma/secondary ; Middle Aged ; Oximes/therapeutic use ; Protein Kinase Inhibitors/adverse effects ; Pyridones/therapeutic use ; Pyrimidinones/therapeutic use ; Skin Neoplasms/drug therapy
SCR Disease Name :
Pili multigemini
Czasopismo naukowe
Tytuł :
Potassium iodide in successful treatment of erythema nodosum-like lesions induced by combination therapy with dabrafenib and trametinib.
Autorzy :
Sawada H; Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan.
Kanehisa F; Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan.
Katoh N; Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan.
Asai J; Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan.
Pokaż więcej
Źródło :
The Journal of dermatology [J Dermatol] 2020 Jan; Vol. 47 (1), pp. e7-e8. Date of Electronic Publication: 2019 Oct 06.
Typ publikacji :
Case Reports; Letter
MeSH Terms :
Dermatologic Agents/*therapeutic use
Erythema Nodosum/*drug therapy
Imidazoles/*adverse effects
Oximes/*adverse effects
Potassium Iodide/*therapeutic use
Protein Kinase Inhibitors/*adverse effects
Pyridones/*adverse effects
Pyrimidinones/*adverse effects
Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Erythema Nodosum/chemically induced ; Female ; Humans ; Imidazoles/therapeutic use ; Melanoma/drug therapy ; Melanoma/genetics ; Melanoma/secondary ; Middle Aged ; Mutation ; Oximes/therapeutic use ; Protein Kinase Inhibitors/therapeutic use ; Proto-Oncogene Proteins B-raf/antagonists & inhibitors ; Proto-Oncogene Proteins B-raf/genetics ; Pyridones/therapeutic use ; Pyrimidinones/therapeutic use ; Skin Neoplasms/drug therapy ; Skin Neoplasms/genetics ; Skin Neoplasms/pathology
Raport

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies